soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 results 💥Soul study group recently shared GLP-1 receptor agonists were developed

They can then adjust the treatment to get the best results

This study has been funded by: : Fondation de la Recherche Mdicale (Equipe FRM DEQ20130326503 to R.J.), Agence Nationale de la Recherche (ANR-2011-BSV1-012-01 MLT2D, ANR-2011-META MELA-BETES, ANR-21-CE18-0023 alloGLP1R) and the Who am I? laboratory of excellence No.ANR-11-LABX-0071 funded by the French Government through its Investments for the Future program operated by The French National Research Agency under grant No.ANR-11-IDEX-0005-01 to R.J

Product offer terms are subject to change

"While we dont expect consumers using GLP-1s to stop eating all less-healthy foods, the volume of purchases may change and overall caloric consumption per person could meaningfully decrease, PwC said